# Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

> **NCT00882258** · PHASE2 · COMPLETED · sponsor: **Repros Therapeutics Inc.** · enrollment: 144 (actual)

## Conditions studied

- Uterine Fibroids

## Interventions

- **DRUG:** 12.5 mg Proellex
- **DRUG:** 25 mg Proellex
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00882258
- **Lead sponsor:** Repros Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 144 (ACTUAL)
- **Last updated:** 2014-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00882258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00882258, "Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00882258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*